News
Updates from Sitryx.
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis10th April 2024Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development4th March 2024Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases4th January 2024Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases1st November 2023Sitryx raises additional $39 million to progress development of disease-modifying therapeutics for chronic autoimmune and inflammatory diseases27th September 2023
Sitryx appoints Carrie Cook as Chief Business Officer15th August 2023
Sitryx CEO, Neil Weir, presents at BioEquity Europe 202317th May 2023
Sitryx CEO, Neil Weir, presents at LSX World Congress 20239th May 2023
Sitryx strengthens early clinical capability with the appointment of Lisa Pierre.17th March 2023Sitryx Therapeutics Announces Participation at the Longwood Healthcare Leaders Pre-JPM Webconference, January 5th & January 6th, 202321st December 2022Sitryx Therapeutics announces presentation at the Stifel 2022 Healthcare Conference10th November 2022Sitryx Therapeutics Announces Participation in Upcoming Conferences8th September 2022
Sitryx Therapeutics to Participate in Wells Fargo Virtual Private Biotech Symposium18th May 2022
Sitryx Therapeutics strengthens leadership team with appointment of Ravi M. Rao as Chief Medical Officer12th April 2022
Sitryx publishes new paper in collaboration with Vanderbilt University16th November 2021
Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement6th July 2021
Our congratulations to Kate Bingham, Sitryx board member and investor, who has been awarded Damehood on the Queen's Birthday Honours List 2021.
Kate has been honoured for her incredible work on the UK Vaccines Taskforce, alongside other leaders in the research community who have played key roles in the battle against Covid-19.
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer15th April 2021
Sitryx appoints Pierre Legault as Chairman of its Board of Directors24th March 2021
Immunometabolism company Sitryx expands into new space at The Oxford Science Park: Second occupier for Bellhouse Building at The Oxford Science Park Oxford, UK.8th March 2021
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines31st March 2020New biopharmaceutical company Sitryx launches with $30 million fundraising to develop disease modifying therapeutics in immunometabolism8th October 2018
